Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) General Information

Description

Rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1). CEACAM1 is a immune modulator blocking its interactions could strengthen immune cells' attack on cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Fano
  • Italy
Primary Industry
Buildings and Property
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Acquirer
Agenus
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Fano
  • Italy

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request a free trial

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)‘s full profile, request access.

Request a free trial

Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) FAQs

  • Where is Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) headquartered?

    Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) is headquartered in Fano, Italy.

  • What industry is Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) in?

    Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)’s primary industry is Buildings and Property.

  • Is Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) a private or public company?

    Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) is a Private company.

  • What is Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)’s current revenue?

    The current revenue for Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) is 000000.

  • Who are Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)’s investors?

    Diatheva has invested in Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1).

  • When was Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) acquired?

    Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) was acquired on 20-Jul-2015.

  • Who acquired Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1)?

    Diatheva (Carcinoembryonic Antigen Cell Adhesion Molecule 1) was acquired by Agenus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »